Tumor lysis syndrome: Pathogenesis, clinical manifestations, definition, etiology and risk factors - UpToDate

uptodate.com · 613 words · saved by 1 readers

INTRODUCTION Tumor lysis syndrome (TLS) is an oncologic emergency that is caused by massive tumor cell lysis with the release of large amounts of potassium, phosphate, and nucleic acids into the systemic circulation. Catabolism of the nucleic acids to uric acid leads to hyperuricemia, and the marked increase in uric acid excretion can result in the precipitation of uric acid in the renal tubules and can also induce renal vasoconstriction, impaired autoregulation, decreased renal blood flow, and inflammation, resulting in acute kidney injury. Hyperphosphatemia with calcium phosphate deposition in the renal tubules can also cause acute kidney injury and in the cardiac conduction system can result in arrhythmias. TLS most often occurs after the initiation of cytotoxic therapy in patients with high-grade lymphomas (particularly the Burkitt subtype) and acute lymphoblastic leukemia. However, TLS can occur spontaneously and with other tumor types that have a high proliferative rate, large tu

Tumor lysis syndrome: Pathogenesis, clinical manifestations, definition, etiology and risk factors INTRODUCTION Tumor lysis syndrome (TLS) is an oncologic emergency caused by massive tumor cell lysis with the release of large amounts of potassium, phosphate, and nucleic acids into the systemic circulation [1]. Catabolism of nucleic acids to uric acid leads to hyperuricemia, and the marked increase in uric acid excretion can result in the precipitation of uric acid in the renal tubules and can also induce renal vasoconstriction, impaired autoregulation, decreased renal blood flow, and…

Tumor lysis syndrome: Pathogenesis, clinical manifestations, definition, etiology and risk factors - UpToDate

related reading